Nya fass.se lanseras förmiddagen lördag 8 november 2025. Läs mer via knappen ovan, "Vi gör om Fass...".

FASS logotyp

Peka på symbolerna och beteckningarna till vänster för en förklaring.

Kontakt

Xatral

Sanofi AB

Filmdragerad tablett 2,5 mg
Avregistreringsdatum: 2020-01-15 (Tillhandahålls ej) (vit, rund, filmdragerad)

Medel vid benign prostatahyperplasi

Aktiv substans:
ATC-kod: G04CA01
För information om det avregistrerade läkemedlet omfattas av Läkemedelsförsäkringen, kontakta Läkemedelsförsäkringen.
Läs mer om avregistrerade läkemedel

Miljöinformation

Miljöpåverkan

Alfuzosin

Miljörisk: Användning av alfuzosin har bedömts medföra försumbar risk för miljöpåverkan.
Nedbrytning: Det kan inte uteslutas att alfuzosin är persistent, då data saknas.
Bioackumulering: Alfuzosin har låg potential att bioackumuleras.


Läs mer

Detaljerad miljöinformation

Environmental Risk Classification


Predicted Environmental Concentration (PEC)

PEC is calculated according to the following formula:

PEC (µg/L) = (A*109*(100-R))/(365*P*V*D*100) = 1.37*10-6*A*(100-R)


PEC = 0.05676 μg/L


Where:

A = 414,3148 kg (total sold amount API in Sweden year 2021, data from IQVIA)


R = 0% removal rate (due to loss by adsorption to sludge particles, by volatilization, hydrolysis or biodegradation)

P = number of inhabitants in Sweden = 10*106

V (L/day) = volume of wastewater per capita and day = 200 (ECHA default) (Ref I)

D = factor of dilution of waste water by surface water flow = 10 (ECHA default) (Ref I)


Predicted No Effect Concentration (PNEC)

Ecotoxicological studies

Algae (Pseudokirchnerellia subcapitata):

EC50 72 h (cell density): 52 700 μg/L

EC50 72 h (area under the growth curve): 46 700 μg/L

EC50 72h (growth rate): > 76 600 µg/L

NOEC72h (biomass): 17 200 µg/L

NOEC72 (growth rate): 36 300 µg/L

(Protocol: OECD 201)

(Ref II)


Crustacean (Daphnia magna):

EC50 48 h (acute immobilization): 314 000 μg/L

(Protocol: OECD 202)

(Ref III)

NOEC21d reproduction per introduced adult: 4 000 µg/L

NOEC21d reproduction per surviving adult ≥ 10 000 µg/L

NOEC21d mortality of adults ≥ 10 000 µg/L

(Ref VII)


Fish (Oncorhynchus mykiss):

LC50 96 h (mortatlity): 1 020 000 μg/L

(Protocol: OECD 203/FDA 4.11)

(Ref IV)


Other ecotoxicity data:

PNEC = 4 000 μg/L /50=80 μg/L


The PNEC (μg/L) was calculated using results from the most sensitive chronic toxicity endpoint and an assessment factor of 50 (two long-term results from species representing two trophic levels). The most sensitive species was Daphnia magna for which the NOEC(21d) was 4 000 μg/L.


Environmental Risk Classification (PEC/PNEC ratio)

PEC/PNEC= 0.05676/80 = 7.1*10-4


PEC/PNEC ≤ 0.1 which justifies the phrase “Use of alfuzosin has been considered to result in insignificant environmental risk”


Degradation

No data available. Therefore, the summary phrase for degradation should be: "The potential for persistence of alfuzosin cannot be excluded, due to lack of data"


Bioaccumulation

Partition coefficient:

Alfuzosin has low potential for bioaccumulation, as indicated by a log Kow of 1.51 at pH 7.4 (experimentally determined by HPLC) (Ref V)


Excretion (metabolism)

Alfuzosin is excreted to 10% as parent compound in urine. There are three metabolic pathways: oxidation, O-demethylation and N-dealkylation. Metabolites are mostly excreted in the feces (75 to 91%). The metabolites are pharmacologically inactive. (Ref VI)


References

  1. ECHA, European Chemicals Agency, 2008 Guidance on information requirements and chemical safety assessment. https://echa.europa.eu/guidance-documents/guidance-on-reach

  2. Sanofi Internal Report: “Toxicity of Alfuzosin to the unicellular green alga, Pseudokirchneriella subcapitata” (OECD 201) (2006)

  3. Sanofi Internal Report: “Acute toxicity of Alfuzosin to the water flea, Daphnia magna, determined under static test conditions” (OECD 202/FDA 4.08) (2006)

  4. Sanofi Internal Report: “Acute toxicity of Alfuzosin to the rainbow trout, Oncorhynchus mykiss, determined under static test conditions” (OECD 203/FDA 4.11) (2006)

  5. Sanofi Internal Report: "Xatral-product monograph" (Rev 2014)

  6. McKeage K. and Plosker G. L. (2002) “Alfuzosin, a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia” Drugs 62 (4): 633-653

  7. Ref: Sanofi, internal report: Alfuzosine HCL: Effect on Daphnia magna in a Semi-Static Reproduction Test. OECD 211. Report #143662221 August 2022